The Alzheimer's Drug Discovery Foundation's mission is to rapidly accelerate the discovery and development of drugs to prevent, treat, and cure #Alzheimers.

Joined February 2009
1,806 Photos and videos
The ADDF has appointed Isobel Coleman as Chief Executive Officer. A global leader across government, nonprofit & private sectors, she will guide the next era of Alzheimer’s research, advancing combination therapies & precision medicine. Read more: bit.ly/4lkx4B2
1
5
846
A review in @JAMAPsych explores 25 years of evidence on lithium as a potential disease-modifying therapy for Alzheimer's. Identifying therapies that target the underlying biology may help accelerate treatments that delay, slow, or prevent the disease. bit.ly/4v1VKSV
6
15
1,356
There's still time to apply for the 2027 ADDF-Harrington Scholar Award. This joint RFP is designed to accelerate innovative research that could treat, prevent, slow, or reverse Alzheimer’s and related dementias. Letters of intent are due June 8. bit.ly/2rEQkiv
1
4
4
385
The ADDF's Aaron Burstein shares with the @washingtonpost how findings from Evoke/Evoke trials are helping researchers better understand biological pathways linked to Alzheimer's and future prevention strategies. washingtonpost.com/health/20…
2
4
471
A recent @Barrons article featured insights from the ADDF's Laura Nisenbaum, who noted that Biogen's #CELIA results suggest "targeting tau can have both biological and clinical effects, which is exactly the kind of signal the field has been working on." barrons.com/articles/biogen-…
1
1
284
Join the ADDF’s CEO Isobel Coleman for a live conversation about the organization’s next chapter, the momentum in Alzheimer’s research, and the potential for AI to accelerate innovation. 📅 June 3, 2026 🕧 12:30 pm ET Register here: bit.ly/4nR4nNh
189
New Phase 2 results from @biogen's CELIA study of #BIIB080 mark an encouraging step toward targeting Alzheimer’s beyond amyloid, reinforcing #tau as a promising target and highlighting momentum toward next-generation therapies. bit.ly/438aL9k
1
1
7
895
Today, #Fujirebio received CE Marking in the European Union for its ADDF-funded pTau217 test, following FDA approval in the U.S. The milestone reflects growing global momentum behind scalable, validated biomarkers and a broader shift in the field. bit.ly/4uftuMf
7
584
Alzheimer's Drug Discovery Foundation retweeted
Alzheimer's disease drug development pipeline: 2026 published today! The 2026 AD drug development pipeline includes 158 unique therapies in 192 trials, marking continued growth in disease-modifying agents, with 35% being repurposed drugs. Thanks @DrJeffCummings @NIHAging @TheADDF
4
32
100
10,743
The Alzheimer’s Drug Development Pipeline 2026 Report reveals that treating the underlying biology is driving the next gen of therapies—75% of drugs target novel aging pathways, paving the way for combination therapy & precision medicine. @DrJeffCummings bit.ly/4tRKsjF
2
269
“Clean” nicotine is being marketed as a brain boost. ADDF’s Yuko Hara shares with @AARP that questions remain about safety and addiction potential. While nicotine may offer short-term cognitive effects, it also comes with risks. bit.ly/4d2KyxQ
132
Exercise, nutrition & social engagement are core components of supporting cognitive health in aging populations. The future lies in precision prevention, integrating lifestyle & therapeutic interventions tailored to each person, similar to heart disease. nbcnews.to/4tlcyn4
1
3
5
283
Alzheimer's Drug Discovery Foundation retweeted
Dinner with the new @TheADDF CEO, what a fantastic lady, and Jane McIntosh, who are a star!
1
2
246
Alzheimer's Drug Discovery Foundation retweeted
Is there anything much better than doing meaningful work with amazing friends? Not sure… Thank you to Heidi McWilliams’ #OpensMinds and the @TheADDF for hosting us in #PalmBeach, proud to be members of the board! @MiiaKivipelto #brainhealth
1
5
260
A new analysis is challenging the impact of anti-amyloid treatments, pointing to limited cognitive benefit and potential risks. As Laura Nisenbaum, ADDF's Executive Director of Drug Development, noted to @AARP, “Not all drugs in this class are the same.” bit.ly/41AyoqB
1
1
1,134
More than 85% say they would take an Alzheimer’s blood test if recommended by their physician, according to a study in Alzheimer’s & Dementia. The ADDF has helped drive this progress through our DxA, bringing the first generation of blood tests to market.🔗bit.ly/4sz7EBy
1
3
7
621
Solving Alzheimer’s is a new Substack from the Alzheimer’s Policy Working Group, featuring insights from frontline clinicians. At the ADDF’s DxA, we’re advancing blood tests and digital tools designed for use in primary care to enable early diagnosis. bit.ly/4srsXVL
159
Gene therapy is a promising yet complex area of research. At the ADDF, we have long considered ApoE4 a critical target. Now, with growing momentum across the field, there is renewed interest in novel gene therapy strategies aimed at addressing it directly. beingpatient.com/apoe4-targe…
1
2
250
Alzheimer's Drug Discovery Foundation retweeted
So, what did MARBLE show? Was CN-105 safe to give to older surgical patients & did it prevent delirium? Stay tuned for the results tomorrow in @JAMANetworkOpen @TheADDF @NIH @ASALifeline @APSForg @snaccprez @SNACCNeuro @Duke_Anesthesia @stanfordanes @AmerDelirium @PeriopCognPIA
1
1
4
239